An Effective and Comfortable Treatment Option for Ocular Itch Associated With Allergic Conjunctivitis - Episode 3
This program is sponsored by Eyevance Pharmaceuticals, a Santen company.
Mark S. Milner, MD
Associate Clinical Professor, Yale University School of Medicine,
New Haven, Connecticut
Director of Cornea, Goldman Eye, Palm Beach Gardens, Florida
Co-Chief Medical Officer, Eyevance Pharmaceuticals, a Santen company
INDICATIONS AND USAGE
ZERVIATE® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.
DOSAGE AND ADMINISTRATION:
Instill one drop of ZERVIATE in each affected eye twice daily (approximately 8 hours apart).
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS:
Contamination of Tip and Solution: As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.
Contact Lens Wear: Patients should be advised not to wear a contact lens if their eye is red. ZERVIATE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIATE. The preservative in ZERVIATE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE.
The most commonly reported adverse reactions occurred in approximately 1%–7% of patients treated with either ZERVIATE or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.
© 2021 Eyevance Pharmaceuticals, a Santen company. All rights reserved.
FLAREX®, TOBRADEX® ST, and ZERVIATE® are registered trademarks of Eyevance Pharmaceuticals, a Santen company.
*All other trademarks are the property of their respective owners.